Legal & General Group Plc Buys Shares of 45,075 ANI Pharmaceuticals, Inc. $ANIP

Legal & General Group Plc purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 45,075 shares of the specialty pharmaceutical company's stock, valued at approximately $3,731,000. Legal & General Group Plc owned about 0.20% of ANI Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $32,992,000. Ranger Investment Management L.P. acquired a new stake in ANI Pharmaceuticals in the 2nd quarter worth approximately $28,406,000. Deutsche Bank AG bought a new stake in ANI Pharmaceuticals during the second quarter worth approximately $26,775,000. Balyasny Asset Management L.P. boosted its position in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after purchasing an additional 276,233 shares during the period. Finally, William Blair Investment Management LLC acquired a new position in ANI Pharmaceuticals during the second quarter valued at approximately $21,372,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on ANIP. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Canaccord Genuity Group lowered their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research note on Monday, August 10th. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $105.83.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $71.23 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $70.15 and a 1 year high of $99.50. The firm has a 50 day moving average of $78.62 and a 200-day moving average of $78.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.64 billion, a P/E ratio of 15.35 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company's revenue was up 25.8% on a year-over-year basis. During the same period last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, Director Thomas Haughey sold 2,000 shares of the company's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the sale, the director owned 38,878 shares in the company, valued at $3,144,452.64. This represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 23,925 shares of company stock worth $1,890,145. Corporate insiders own 8.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source